UCLA Ronald Reagen
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
David
foresiGHt, NCT04615273 / 2020-000929-42: A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Completed
3
264
Europe, Canada, Japan, US, RoW
Lonapegsomatropin, Placebo, Somatropin
Ascendis Pharma Endocrinology Division A/S
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
11/23
12/23
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
INTASYL PH-762, NCT06014086: Intratumoral PH-762 for Cutaneous Carcinoma

Recruiting
1
30
US
PH-762
Phio Pharmaceuticals Inc., Prosoft Clinical
Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
06/25
09/25
SRMR, NCT06059521: Software Refraction With Mobilerone Versus Retinoscopy

Recruiting
N/A
120
RoW
Software refraction with Eye Test Technology in a mobilerone, Online refraction or App refraction with Eye Test Technology, Retinoscopy, Refraction by retinoscopy
Beijing Airdoc Technology Co., Ltd., University of Notre Dame Australia
Myopia, Myopia, Moderate, Astigmatism
12/25
12/30

Download Options